FDA approves drug for autism irritability

Oct 13, 2006

The U.S. Food and Drug Administration approved Risperdal to treat irritability in autistic children and adolescents.

This is the first time the FDA approved a drug to treat behavior-related problems associated with autism in children, the FDA said in a news release. The drug can be used to treat aggression, deliberate self-injury and temper tantrums, all of which are classified under irritability.

Risperdal is an anti-psychotic drug used to treat adults with schizophrenia, the FDA said. In 2003, it was also approved as a short-term treatment for adults with acute manic episodes or extreme mood swings.

Risperdal is manufactured by Janssen Pharmaceutica N.V. in Beerse, Belgium.

Copyright 2006 by United Press International

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Advancing medicine, layer by layer

Jul 02, 2014

Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor ...

Bone marrow-on-a-chip unveiled

May 05, 2014

The latest organ-on-a-chip from Harvard's Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could ...

Recommended for you

Boxed warnings are common in novel therapeutics

22 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

23 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0